NAS
IOVA icon

Nykredit A/S’s Iovance Biotherapeutics IOVA Stock Holding History

Nykredit A/S’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4K Buy
+3,222
New +$12.2K ﹤0.01% 1827

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Nykredit A/S's IOVA Position: Q2 2026 in Review

Nykredit A/S opened a new position in Iovance Biotherapeutics (IOVA) in Q2 2026: 3,222 shares worth $13.4K. The stake represents ﹤0.01% of the portfolio and ranks #1827 among its holdings.

209 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Nykredit A/S held 3,222 shares of Iovance Biotherapeutics worth $13.4K as of Q2 2026.
  • Iovance Biotherapeutics was a new Nykredit A/S position in Q2 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1827 holding.
  • 209 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.